Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 621 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Veteran Avoided The Barber For 6 Years After He Left The... February 28, 2020 Impressive Responses to PD-1 Blockade in a Large Cohort of Children... January 17, 2022 Young Mom Gives Birth To Healthy Baby Boy In The Midst... June 26, 2020 FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma March 25, 2022 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Retifanlimab EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer
